These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

4502 related items for PubMed ID: 18773960

  • 21. A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function.
    Chang GJ, Mahanty HD, Vincenti F, Freise CE, Roberts JP, Ascher NL, Stock PG, Hirose R.
    Clin Transplant; 2000 Dec; 14(6):550-4. PubMed ID: 11127307
    [Abstract] [Full Text] [Related]

  • 22. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.
    Guethoff S, Stroeh K, Grinninger C, Koenig MA, Kleinert EC, Rieger A, Mayr T, von Ziegler F, Reichart B, Hagl C, Schramm R, Kaczmarek I, Meiser BM.
    J Heart Lung Transplant; 2015 May; 34(5):634-42. PubMed ID: 25701373
    [Abstract] [Full Text] [Related]

  • 23. Early sirolimus therapy in renal transplant recipients at high risk: is it justified?
    Halim MA, Al-Otaibi T, Johny KV, Hamid MH, Al-Waheeb S, Hasaneen H, Awadain WH, Nawas KM, El-Sayed A, Said T, Nair MP, Nampoory MR.
    Transplant Proc; 2009 Sep; 41(7):2784-8. PubMed ID: 19765435
    [Abstract] [Full Text] [Related]

  • 24. Randomized trial of 3 maintenance regimens (TAC/SRL vs. TAC/MMF vs. CSA/SRL) with low-dose corticosteroids in primary kidney transplantation: 18-year results.
    Ciancio G, Gaynor JJ, Guerra G, Roth D, Chen L, Kupin W, Mattiazzi A, Ortigosa-Goggins M, Moni L, Burke GW.
    Clin Transplant; 2020 Dec; 34(12):e14123. PubMed ID: 33070366
    [Abstract] [Full Text] [Related]

  • 25. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 26. Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: observational results at 24 and 36months after transplantation.
    Guba M, Pratschke J, Hugo C, Krämer BK, Pascher A, Pressmar K, Hakenberg O, Fischereder M, Brockmann J, Andrassy J, Banas B, Jauch KW, SMART-Study Group.
    Transpl Int; 2012 Apr 15; 25(4):416-23. PubMed ID: 22320241
    [Abstract] [Full Text] [Related]

  • 27. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus.
    de Sandes-Freitas TV, Felipe CR, Campos ÉF, de Lima MG, Soares MF, de Franco MF, Aguiar WF, Tedesco-Silva H, Medina-Pestana JO.
    Transplantation; 2015 Nov 15; 99(11):2372-81. PubMed ID: 25929604
    [Abstract] [Full Text] [Related]

  • 28. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
    Oh CK, Huh KH, Ha J, Kim YH, Kim YL, Kim YS.
    Transplantation; 2015 Jan 15; 99(1):180-6. PubMed ID: 24983307
    [Abstract] [Full Text] [Related]

  • 29. Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine.
    Stegall MD, Simon M, Wachs ME, Chan L, Nolan C, Kam I.
    Transplantation; 1997 Dec 27; 64(12):1695-700. PubMed ID: 9422404
    [Abstract] [Full Text] [Related]

  • 30. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 31. Randomized trial of cyclosporine and tacrolimus therapy with steroid withdrawal in living-donor renal transplantation: 5-year follow-up.
    Lee YJ, Kim B, Lee JE, Kim YG, Kim DJ, Kim SJ, Joh JW, Oh HY, Huh W.
    Transpl Int; 2010 Feb 27; 23(2):147-54. PubMed ID: 19744223
    [Abstract] [Full Text] [Related]

  • 32. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.
    Jones-Hughes T, Snowsill T, Haasova M, Coelho H, Crathorne L, Cooper C, Mujica-Mota R, Peters J, Varley-Campbell J, Huxley N, Moore J, Allwood M, Lowe J, Hyde C, Hoyle M, Bond M, Anderson R.
    Health Technol Assess; 2016 Aug 27; 20(62):1-594. PubMed ID: 27578428
    [Abstract] [Full Text] [Related]

  • 33. High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study.
    Burkhalter F, Oettl T, Descoeudres B, Bachmann A, Guerke L, Mihatsch MJ, Dickenmann M, Steiger J.
    Transplant Proc; 2012 Dec 27; 44(10):2961-5. PubMed ID: 23195006
    [Abstract] [Full Text] [Related]

  • 34. Steroid-avoidance immunosuppression regimen in live-donor renal allotransplant recipients: a prospective, randomized, controlled study.
    Nematalla AH, Bakr MA, Gheith OA, Elagroudy AE, Elshahawy el-M, Aghoneim M.
    Exp Clin Transplant; 2007 Dec 27; 5(2):673-9. PubMed ID: 18194120
    [Abstract] [Full Text] [Related]

  • 35. New approaches to de novo immunosuppression and steroid elimination.
    Lebranchu Y.
    Transplant Proc; 2009 Dec 27; 41(6 Suppl):S39-41. PubMed ID: 19651295
    [Abstract] [Full Text] [Related]

  • 36. Thymoglobulin induction in liver transplant recipients with a tacrolimus, mycophenolate mofetil, and steroid immunosuppressive regimen: a five-year randomized prospective study.
    Boillot O, Seket B, Dumortier J, Pittau G, Boucaud C, Bouffard Y, Scoazec JY.
    Liver Transpl; 2009 Nov 27; 15(11):1426-34. PubMed ID: 19877264
    [Abstract] [Full Text] [Related]

  • 37. Steroid withdrawal at 3 months after kidney transplantation: a comparison of two tacrolimus-based regimens.
    Wlodarczyk Z, Walaszewski J, Perner F, Vitko S, Ostrowski M, Bachleda P, Kokot F, Klinger M, Szenohradszky P, Studenik P, Navratil P, Asztalos L, Rutkowski B, Kalmar KN, Hickey D.
    Transpl Int; 2005 Feb 27; 18(2):157-62. PubMed ID: 15691267
    [Abstract] [Full Text] [Related]

  • 38. A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology.
    Stevens RB, Foster KW, Miles CD, Kalil AC, Florescu DF, Sandoz JP, Rigley TH, Malik T, Wrenshall LE.
    PLoS One; 2015 Feb 27; 10(10):e0139247. PubMed ID: 26465152
    [Abstract] [Full Text] [Related]

  • 39. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.
    Rivelli RF, Gonçalves RT, Leite M, Santos MA, Delgado AG, Cardoso LR, Takiya CM.
    Nephrology (Carlton); 2015 Mar 27; 20(3):168-76. PubMed ID: 25404086
    [Abstract] [Full Text] [Related]

  • 40. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
    Vacher-Coponat H, Moal V, Indreies M, Purgus R, Loundou A, Burtey S, Brunet P, Moussi-Frances J, Daniel L, Dussol B, Berland Y.
    Transplantation; 2012 Feb 27; 93(4):437-43. PubMed ID: 22228415
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 226.